Digestive and Colorectal Surgery and Centre for Minimal Invasive Surgery, University of Turin, Corso A. M. Dogliotti, 14, 10126 Turin, Italy.
Surg Endosc. 2012 Sep;26(9):2609-16. doi: 10.1007/s00464-012-2240-5. Epub 2012 Apr 5.
The purpose of this study was to evaluate short-term and oncologic outcomes of laparoscopic resection (LR) for patients with symptomatic stage IV colorectal cancer compared with open resection (OR).
This study is a retrospective analysis of a prospective database. Patients with a minimum follow-up of 12 months after LR or OR for metastatic colorectal cancer were included. All analyses were performed on an "intention-to-treat" basis.
A total of 162 consecutive patients submitted to LR and 127 submitted to OR were included. In the LR group, conversion rate was 26.5 %, mostly due to locally advanced disease (88.4 %). A greater risk of conversion was observed among patients with a tumor size greater than 5 cm regardless the tumor site (P = 0.07). Early postoperative outcome was significantly better for LR group, with a shorter hospital stay (P = 0.008), earlier onset of adjuvant treatment, and similar postoperative complications (P = 0.853) and mortality rates (P = 0.958). LR for rectal cancer was associated with a higher morbidity compared with colon cancer (P = 0.058). During a median follow-up time of 72 months, there was no significant difference in overall survival between the two groups (P = 0.622).
LR for symptomatic metastatic CRC is safe and, compared with OR, is associated with a shorter hospital stay and with similar survival rates. Concerns remain about LR of bulky tumors and rectal cancers due to the increased risk of conversion and postoperative complications.
本研究旨在评估腹腔镜切除术(LR)治疗有症状的 IV 期结直肠癌患者与开放切除术(OR)相比的短期和肿瘤学结果。
这是一项前瞻性数据库的回顾性分析。纳入了接受 LR 或 OR 治疗转移性结直肠癌后至少随访 12 个月的患者。所有分析均基于“意向治疗”原则进行。
共纳入 162 例连续接受 LR 和 127 例接受 OR 的患者。在 LR 组中,转化率为 26.5%,主要是由于局部晚期疾病(88.4%)。肿瘤大小大于 5cm 的患者无论肿瘤部位如何,转换的风险都更高(P=0.07)。LR 组的早期术后结果明显更好,住院时间更短(P=0.008),辅助治疗开始更早,术后并发症和死亡率相似(P=0.853 和 P=0.958)。LR 治疗直肠癌的发病率高于结肠癌(P=0.058)。在中位随访时间为 72 个月时,两组的总生存率无显著差异(P=0.622)。
LR 治疗有症状的转移性 CRC 是安全的,与 OR 相比,LR 与较短的住院时间和相似的生存率相关。由于转换和术后并发症的风险增加,对于大块肿瘤和直肠癌症的 LR 仍存在担忧。